EGFR Phosphorylation of DCBLD2 Recruits TRAF6 and Stimulates AKT-promoted Tumorigenesis
Haizhong Feng,Giselle Y. Lopez,Chung Kwon Kim,Angel Alvarez,Christopher G. Duncan,Ryo Nishikawa,Motoo Nagane,An-Jey A. Su,Philip E. Auron,Matthew L. Hedberg,Lin Wang,Jeffery J. Raizer,John A. Kessler,Andrew T. Parsa,Wei-Qiang Gao,Sung-Hak Kim,Mutsuko Minata,Ichiro Nakano,Jennifer R. Grandis,Roger E. McLendon,Darell D. Bigner,Hui-Kuan Lin,Frank B. Furnari,Webster K. Cavenee,Bo Hu,Hai Yan,Shi-Yuan Cheng
DOI: https://doi.org/10.1172/jci73093
2014-01-01
Neuro-Oncology
Abstract:Aberrant activation of EGFR in human cancers promotes tumorigenesis through stimulation of AKT signaling. Here, we determined that the discoidina neuropilin-like membrane protein DCBLD2 is upregulated in clinical specimens of glioblastomas and head and neck cancers (HNCs) and is required for EGFR-stimulated tumorigenesis. In multiple cancer cell lines, EGFR activated phosphorylation of tyrosine 750 (Y750) of DCBLD2, which is located within a recently identified binding motif for TNF receptor-associated factor 6 (TRAF6). Consequently, phosphorylation of DCBLD2 Y750 recruited TRAF6, leading to increased TRAF6 E3 ubiquitin ligase activity and subsequent activation of AKT, thereby enhancing EGFR-driven tumorigenesis. Moreover, evaluation of patient samples of gliomas and HNCs revealed an association among EGFR activation, DCBLD2 phosphorylation, and poor prognoses. Together, our findings uncover a pathway in which DCBLD2 functions as a signal relay for oncogenic EGFR signaling to promote tumorigenesis and suggest DCBLD2 and TRAF6 as potential therapeutic targets for human cancers that are associated with EGFR activation.